GSK plc Investor Event Transcript, Nov 17, 2026
GSK plc (GSK)
GSK plans to deliver 1.9 billion of costs by 29 through restructuring across its value chain, with most of the savings reinvested in R&D. It also says it will not slow down on BD. AI summary
Conference Transcript - GSK 2026-11-17
Michael Leuchten, Analyst — Jefferies
Okay. Good morning. Welcome, everybody, to day two of the Jefferies Healthcare Conference this year. My name is Michael Leuchten. I'm one of the European Pharma Analysts at Jefferies. Thank you for joining us early. It's my pleasure to host GSK today. We've got David Radford, the head of BD at GSK or president of BD, also responsible for VEV. I think we'll do a little bit on Veeve, and then we'll do BD, and then a little bit broader on GSK and the recent changes. I hope I can make that work in 25 minutes. So, David, thank you for joining. Maybe just sort of starting with Veeve, I think you chaired it since 2011, and looking back, what would you say are the two or three decisions that most changed the direction of the business, And what lessons have been most relevant as we think about your transition of the portfolio to the long-acting injectables? Great.
David Radford, Other
Well, good morning, everyone. Thanks, Michael, for having us. Thanks for Jeffrey's hosting, everyone. Next year, you just need to fix the weather a little bit, I think. So it's a great question on B. I mean, I think probably two things, actually. If you go way back, when we developed dolotegravir, which is the oral integrase inhibitor that's really become the backbone standard of care. We knew we had a very potent molecule from the animal studies from phase two, 50 milligrams, very well tolerated. And I think one of the key things we did in that phase three development program was not just study dolotegravir in virally suppressed patients, which was the normal, but we ran in parallel all types of people living with HIV. So people who had high viral load, naive patients, and so forth. So when we got approval for dolotegravir, we had a very, very broad label. And obviously, it's gone on to be an enormous medicine. And then I think the second key thing was a decision we took over a decade ago to really focus our R&D money on long acting. And that wasn't a completely obvious decision, because the daily orals in HIV had become very, very effective. If you talk to most doctors at that time, they were very satisfied. But there were two sort of key insights. One was patient insight. There were quite a significant number of people living with HIV that did not want to take daily oral pills every day. They felt a degree of stigma, anxiety, hadn't necessarily disclosed their status, and they really wanted to move to a long-acting injection. And also, unfortunately, the United States of the 1.2 million people living with HIV, only 60% or so are virally suppressed, despite the modern medicine. And that's everything to do with access to the healthcare system. So there's still over 400, 400 to 500,000 Americans that living in the rural South, lower income inner city, particularly African Americans who aren't virally suppressed. And the only way to really treat that population effectively is with a long-acting injection. So we invested in that. Obviously, we launched the first medicine, Cabernuva, for treatment. That's every two months, and that's now grown into a very significant medicine and doing extremely well.
Michael Leuchten, Analyst — Jefferies
Great. Thank you. And then maybe one more on beef before I think most people are probably more interested in sort of BD and GSK going forward. And so long-acting strategy, there is Cabinuva Q4M, so every four months. Then there is the every six-monthly, which is a bit further out. Can you just talk about timelines? Can you talk about, there was a slight hiccup with the Q4M PKPD study. We're going to get Quattro next year, which is the treatment every four months, Cabinuva. Just paint that picture. Like, what's the confidence into Cabinuva Q4M and into every six months with 149 and 499?
David Radford, Other
Yes, I mean, you have to separate the treatment market, which is about 90% of the overall HIV market, over £22 billion from the PrEP prophylactic market, which is predominantly a US market, about £3 billion. So in treatment, we have the first and only long-acting... Uh, medicine on the market. As I said, Cabinuva doing very, very well now with very comprehensive data set. Uh, we have a reformulated version of Cabotegravir and Rapivirin in a pivotal study. Uh, the Quattro study that you referred to that has fully recruited and we expect data on that, uh, probably the second half of next year. Um, so that would potentially be on the market in 2028. And then we are developing a next generation integrase with a much broader resistance barrier, 184, with our own capsid inhibitor. Um, and that, that has the potential to be a sixth monthly regimen. Um, both of those molecules are in phase two studies at the moment and we're figuring out the formulation and the dose. Um, and we would hope to put those into pivotal studies, um, probably somewhere around mid, uh, 28. Uh, and then if we do that, we could potentially, um, get that on the market, uh, early 2030s. And I think that, you know, as we move from every two months to every four months, and then every six months, we will see a significant increase in the penetration of long acting in the overall HIV treatment market. And, you know, certainly when we get to every six months, I think up to, you know, at least half the market could potentially switch. So that's very exciting. And then in PrEP, as you said, we have Appertude, which is every two months, doing pretty well in a growing market, and we've got data in-house on the four-month version of that, and we're in discussions with the regulator with that. I'm not going to say more about that other than we're very, very confident in the formulation that we've got, and the formulation, actually, of PrEP and the four-month version of... Cabotegra is the same.
Michael Leuchten, Analyst — Jefferies
Go ahead. Okay. Amazing. So let's maybe pivot to BD. You've overseen corporate development across several different strategic eras at GSK. Can you talk about the philosophy of BD today and how that's changed and sort of what's distinctive about the current approach that you're pursuing?
David Radford, Other
I mean, we've been very active in BD this year, and actually the last two or three years. I mean, ever since really, we demerged the Halium business, the consumer business, reset the balance sheet and became a pure play biopharma business. So like most large cap farmers, you know, BD is an essential part of how we allocate capital. There's obviously fantastic science throughout the world to access. So this year, we've done three pieces of M&A. We've bought Nuvalent in the middle of the year, Boston-based, Precision Oncology Company. That was important to us because it was an important building step as we redevelop our oncology business, which is now going extremely well. And it gave us an entry into lung cancer for the first time. It has two precision molecules for ALK and ROS1 inhibitor. The ROS1's been approved with the ALK we expect to be approved any day. So that's going well. And behind that, in our own portfolio, we've got a B7H3 ADC from Hansel that could also, we're in a pivotal study for small cell lung cancer at the moment, and potentially we're going to non-small cell lung cancer. So there's no doubt under Luke Miles' leadership, GSK is very much back in oncology, both blood cancers and solid tumors. We've got a pretty extensive portfolio now. We're allocating a lot of capital to it, and you should certainly expect us to do more BD and oncology. We bought wrapped pharma in the start of the year that has a food allergy antibody, very similar, the same epitope as Zola. Food allergy, as you can imagine, is growing very, very fast. Something like 18 million people in the United States have a significant food allergy. But the rapt is really sort of quite indicative of the deals we like, where there is some level of scientific de-risking, normally the target. So in this case, the epitope, as I said, is, I think, de-risked from Zolaire, but with very, very clear differentiation. And in all the deals we do, being absolutely clear what the point of differentiation is, is absolutely critical. In this case, the dosing regimen is every 12 weeks. It has a much simpler dosing regimen than Zola. And it also, the problem with Zola is because of the maximum dosing, it can't be used in... People with food allergies over a certain BMI and weight, whereas R1 can. So that's exciting. And then we've done a whole bunch of licensing deals, some from the US, some from China. We've been pretty active in China. I think we will continue to be. Most of our Chinese licensing is phase one. So we like, and we've obviously done deals with Hengoroy, with Hanzo. We're very excited about the ADCs that I talked about that we've got from Hanzo. But phase one is a sort of sweet spot because you've got some human data, but then the ability to run the pivotal studies in the markets, you want regulatory approval, and also to move the supply chains across. So we've been active. You should certainly expect us to continue to be active as we finish this year and go into next year.
Michael Leuchten, Analyst — Jefferies
Great. Can we maybe go a little bit deeper into that point? You did New Valent. We like that deal a lot, but you used a lot of your balance sheet capacity. We sort of look at a total of capital deployed. Is now a reload time? Do you have capacity to do sizable deals or is it more consolidating now?
David Radford, Other
It's a bit of both. I mean, we've definitely got more balance sheet capacity available. We're really governed by our credit rating. We like staying at A2. But of course, the cash flow of the business is extremely strong, we expect. Cash flow from operations to be over £10 billion this year. So the balance sheet is replenishing pretty fast. I think we're about 1.8 billion times, 1.8 times levered at the moment. It's not just balance sheet capacity, it's P&L capacity and also management capacity. We've got plenty to do. But you should, as I said, you know, we will do more and we've got more capacity. I wouldn't expect us to do another $10 billion deal this week. We'll leave that to others. But most of the deals up to Nuvalent were sort of typically in the $2, $3 billion range, and we quite like that level.
Michael Leuchten, Analyst — Jefferies
Got it. And then maybe another way to look at BD is, so the assets that you acquired, you sort of said you go after the differentiation, it fits your setup already. What you haven't done is platform deals, or at least not yet. Is that something that you don't think GSK needs right now to branch out into other areas, or is it just a timing question?
David Radford, Other
I mean, it depends what you mean by platform deals. I mean, we access a lot of technology. We obviously, like all pharma companies, we're doing a lot on AI. Part of that actually is accessing human databases. So we have access here in the UK to the biobank, to the NHS, we've got access to things like Tempest and oncology, some of the insurance data in the US. So, you know, and I think increasingly, I mean, the algorithms matter, but having the Quality, longitudinal human data. To help in the work we're doing, combining that with AI to identify novel targets is critical. So there's plenty going on there. We access all sorts of different technologies. I will give our friends at Angentex who are in the room a plug. It's a UK-based biotech where we're working and collaborating with in liver disease. So we do, I mean, they tend to be smaller at an earlier stage. They'll probably get less headlines, but we do plenty.
Michael Leuchten, Analyst — Jefferies
Okay, got it. And maybe because you mentioned Hanzo, I think you moved early on that. You were one of the earlier companies to go into these sort of deals with China. It's become more crowded. Is that still a source of deal flow for you? Do you think it'll accelerate quality of assets, readability of Chinese data into the rest of the world? You mentioned you got there, but you had to find out ways to replicate data for regulatory approval outside China.
David Radford, Other
We never start from the point of view that we're going to go to China and see what we can find. We identify a mode of action or a molecule we particularly want and then decide who has the best one, and that's exactly what happened with Hanzo. So we were very keen as we built our oncology business to have a B7H3, B7H4, ADC, two ADCs, and we looked around. Obviously, Merck licensed the Daiichi ones for quite a lot of money. We did a lot of work with all the different options, and we ended up doing the deals with Hanzo, which has worked so far incredibly well. I mean, I think it's interesting because particularly in oncology, I mean, as you know, China... So Hanzo has the rights in China, we have the rest of the world. They're running about 18 months ahead of us with the studies that they are doing in China. And that's incredibly informative, because it's a good proof point. So they already have, they showed very good data with overall survival benefit, world lung. In small cell lung cancer in second line, we're running the pivotal study there. They showed great data in osteosarcoma. They're running studies in non-small cell lung cancer and a whole range of other solid tumors. So that is useful data because it enables us to sort of make our own choices of exactly which tumor types to go for. And I have to say so far. And the data that we've got from the Western studies, mainly phase two studies, has replicated almost exactly. And we're super excited about both of those ADCs. As I said, small cell lung cancer is going very, very fast and potentially have the opportunity to file that. As early as next year. And then we have five pivotal studies now running on B7H4 in ovarian and endometrial cancer, first and second line. So I think, look, China, we all know the innovation has moved very fast. It is in certain areas. They're extremely good at protein engineering. They're extremely good at building ADCs. They've moved from sort of fast followers to probably in some cases best in class. We've also licensed some tri-specifics and bi-specifics from Chymogen and HutchMed and so forth. So particularly in that protein, complex protein molecules, they're very good. But we're still doing plenty of deals in America and elsewhere.
Michael Leuchten, Analyst — Jefferies
I want to try to link sort of the V, BD, and PNL comment that you make together in a minute. But before we do that... With your experience on BD, there have been transactions that unfortunately haven't worked out like Bell is. But when you take a step back, what's the biggest source of value leakage when you do deals? Is it cultural friction, development slower, loss of key scientists?
David Radford, Other
Well, the biggest sort of leakage is when the molecule doesn't work. I mean, that's fairly obvious. I mean, I would say we put a lot of attention on CMC, and CMC rarely... It derails an asset, but it can very easily slip timelines. And one of the key parts of due diligence we do is really, you know, thinking through the robustness of CMC and whether it's consistent with the timelines that we build in the models or the timelines that are stated. So, and there's lots of ways it can go wrong. And as we're doing more and more complicated medicines. So it's, you know, it's always a combination of things. I mean, I have to say overall, I mean, you're right, obviously, Bellis, which was reasonably high risk, didn't work out. But most of the recent deals that we've done, and we do a very serious exercise every year to compare the original assumptions with the most recent forecasts, are running quite a way ahead. So the Sierra acquisition, where we got a Jara in myelofibrosis, is flying. We talked about the ADCs, actually, even to SARO, because while Cedula has probably underformed a little bit, Jim Purley is doing extremely well, the Stolomab in endometrial cancer and just about to be rectal cancer. So, yeah, overall, I think, you know, the BD has been a key driver of our growth.
Michael Leuchten, Analyst — Jefferies
Got it. And then if we try to link the VEV commentary, the BD and PLN impact and then sort of new GSK, if I can call it that together. So 27 is a year where I think things are relatively normal. And from 28, it gets a little bit more choppy because there are some lots of exclusivities that are hard to fade in. High profitable stuff slowing down gives you a negative mix effect. You've announced a major restructuring program, but then you have done BD and you continue to do BD. Can you talk a little bit about the shape of... That balance into 28-29 and then beyond where the long-acting new generation comes in, like that in-between period, where do you think the main focus is? Is it the reduction program? Is it do more BD to? To pad out the assets that can go into market quickly? Is it all of the above?
David Radford, Other
Well, I think it's all of the above, but I particularly flag we've had over 20, I think it's now 22 phase three starts this year. So obviously, as those read out next year and in 27 and 28, you know, that is the backbone of the future growth of GSK. And I think, as you said, the way to think about GSK is we're performing very strongly the last few years. We've upgraded again this year to mid-single-digit or the top end of our 3% to 5% sales growth and the top end of our 7% to 9% operating profit growth. Next year, there's puts and takes, but broadly, as you've said, we're guide next year, but we certainly expect to grow strongly next year and not decline the operating margin. As we go into 28, the Dolotegravir patent expiries start on a major way. So we lose in April 28 in the US, Tifike and Triumek. Devato is right at the end of 29. Europe is also in 29. So the HIV business will decline. Particularly in 20, I mean, to some degree in 28, but the main declines will be in 29 and 30, despite the fact that long acting will continue to grow. And offsets some of the oral decline. But overall, we're very clear, we expect GSK to grow through the dolotegravir period, which is why we've given an outlook of more than 40 billion in 2031, recognizing sales today of plus or minus this year around 35 billion. And that is driven mainly by the specialty business that is already launched, our growing oncology business, medicines like Nucala, Extensure in respiratory. As well as vaccines. And then I think the most exciting thing about GSK, and you guys on the sell side need to focus a little bit more on it as we move forward, is as we get to the other side of doletogravir in the early 2030s, I think we really have the ability to accelerate our growth to a top quartile in the industry. Because as the pipeline comes through, the ADCs, the investments we've made in liver disease with things like FGF21, our biologics in respiratory, so our long-acting T-slip, our long-acting IL-33, our long-acting in HIV, vaccines, where we have our flu mRNA program already in pivotal studies, and all the various tumor types in oncology. And then our precision oncology and valsatinib, you put all that together. Once with the other side of the patent expiry, I think we can really accelerate very strongly. And that should lead to a significant rewriting. Obviously, there's a lot of execution attached to that we recognize that. We're very focused, I think, on execution. Part of that is taking out or delivering 1.9 billion of costs by 29. Most of that will be reinvested in R&D. And that's a key part of it. And of course, on top of all of that, we're not going to slow down on BD.
Michael Leuchten, Analyst — Jefferies
Got it. And then maybe in the last few minutes, I think you joined GSK in 1994. So you've sort of seen a number of strategic approaches. The restructuring program that you mentioned, the 1.9 billion, can you talk about? How that compares to maybe prior programs and also interested in the decision to move from Stevenage to Cambridge from an R&D perspective, like how different is that and what impact do you think that will have on the organization?
David Radford, Other
Well, I think, I mean, look, restructuring, we haven't done a major restructuring for five years. So it felt like the right time. And obviously, with a new CEO, I mean, it is across the whole value chain. There's opportunities in our supply chain. As we move to more specialty, some of the older manufacturing sites that serve the general medicines business have become surplus to requirements. Of course, with technology, we've got multiple service centers around the world, but there is an opportunity to consolidate those to some degree and also drive even more automation into those and so forth. So the restructuring is not particularly different or surprising compared to what a lot of multinationals are doing, really taking advantage of tech. I mean, in terms of the move from Stevenage to Cambridge, I mean, I think that makes complete sense. It's been relatively uncontroversial. I think, you know, we're very fortunate in this country. The Cambridge ecosystem is amazing and growing. Stephenage has been a great site for 30 years, but it's too large for the way we now work. It's got too many wet labs, and I think the scientists increasingly want to be part of a broader ecosystem and have the opportunity to interact, so we will do that over the next two years. Um, most people at Stevenage, uh, will move to Cambridge. Um, a few will move to our, uh, manufacturing and pilot plant site in where, where we do a lot of drug formulation work. Um, but, you know, we're pretty excited about that and, um, excited about being part of the, uh, Cambridge ecosystem.
Michael Leuchten, Analyst — Jefferies
Perfect. And then last question, if, uh, let's say in five years time, uh, we, we do this again. In rear view mirror, what do you think is the most important thing GSK needs to get right? So in five years time, we have a conversation where we go.
David Radford, Other
I would love to think in five years time, we have a really, really material and fast growing oncology business. I mean, it's about two billion pounds today. I think it could be multiples bigger than that.
Michael Leuchten, Analyst — Jefferies
Got it.
David Radford, Other
Great.
Michael Leuchten, Analyst — Jefferies
Right on time. Thank you. Thanks.